Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0~102.0% Factory

Lenvatinib Mesylate (CAS: 857890-39-2) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. Lenvatinib Mesylate is a receptor tyrosine kinase (RTK) inhibitor that has selectivity for VEGFR2. It exhibits antineoplastic activity, and has been indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Lenvatinib Mesylate was first approved by the U.S. Food and Drug Administration (FDA) on Feb 13, 2015, then approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Mar 26, 2015, and approved by European Medicine Agency (EMA) on May 28, 2015. It was developed and marketed as Lenvima® by Eisai. Lenvatinib Mesylate is an oral multiple receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors, in addition to other proangiogenic and oncogenic pathway-related tyrosine kinases thought to be involved in tumor proliferation. It is indicated for the treatment of progressive radioiodine-refractory differentiated thyroid cancer. Lenvima is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing. LENVIMA is used along with another medicine called everolimus to treat adults with a type of kidney cancer called advanced renal cell carcinoma (RCC) after one course of treatment with another anti-cancer medicine.